Fri, June 17, 2011
Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ]: Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011
Tue, June 7, 2011
Mon, June 6, 2011
Sat, June 4, 2011
Fri, June 3, 2011
Thu, June 2, 2011
Wed, June 1, 2011
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011

Abiomed Announces Appointment of Paul G. Thomas to Board of Directors

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. ment-of-paul-g-thomas-to-board-of-directors.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed, Inc. ] (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Paul G. Thomas to the Companya™s Board of Directors.

"This is an exciting time for Abiomed and I am looking forward to working with the team"

Currently, Mr. Thomas is Chief Executive Officer and Founder of Roka Bioscience, a company focused on the development and commercialization of molecular assays and is a Director of Orthovita, Inc. (NASDAQ: VITA). Mr.Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation until it was acquired by KCI in 2008 and also held various senior positions during his tenure of 15 years with Ohmeda. Mr.Thomas received his M.B.A. degree from Columbia University Graduate School of Business, completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science and received his B.S. degree in Chemistry from St. Michaela™s College in Vermont.

"We are extremely pleased and fortunate to have Paul join the Abiomed Board of Directors,a said MichaelR. Minogue, Chairman, President and Chief Executive Officer of Abiomed. aPaula™s previous experience and record of achievement at LifeCell Corporation is well recognized. His guidance will be invaluable as we execute our plan toward driving further adoption of the Impella heart recovery platform.a

"This is an exciting time for Abiomed and I am looking forward to working with the team," said Mr. Thomas.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.